Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
Provided By PR Newswire
Last update: May 14, 2025
Updated data from the Phase 1 ENABLE clinical trial of ELVN-001 in CML to be presented at the EHA 2025 Congress in June
EHA abstract reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, and ELVN-001 remains well-tolerated with 74 patients enrolled
Read more at prnewswire.com
